Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | DRD1 | P21728 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17064284 | 0.98 | AOC3 (0.96) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| SCHEMBL28166588 | 0.94 | AOC3 (0.88) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| SCHEMBL8817598 | 0.86 | AOC3 (1.00) | AOC3SIGMAR1TAAR1 | |
| Hydrochloric Acid SCHEMBL17064263 | 0.84 | AOC3 (0.95) | AOC3SIGMAR1TAAR1 | |
| SCHEMBL119103 | 0.82 | SIGMAR1 (0.83) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| SCHEMBL12902332 | 0.82 | SIGMAR1 (0.88) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| Bromide SCHEMBL5091341 | 0.80 | SIGMAR1 (0.80) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| Iodide SCHEMBL5088132 | 0.80 | SIGMAR1 (0.80) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL5091388 | 0.80 | SIGMAR1 (0.80) | AOC3SIGMAR1CHRM2HTR1AADRA2A | |
| Water SCHEMBL11773331 | 0.80 | SIGMAR1 (0.80) | AOC3SIGMAR1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209446-A1 | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | MEIJI SEIKA KAISHA LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1479687-A1 | NOVEL 15-MEMBERED CYCLIC AZALIDE, NOVEL 16-MEMBERED CYCLIC DIAZALIDE DERIVATIVE, AND PROCESS FOR PRODUCING THESE | MEIJI SEIKA KAISHA LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209446-A1 | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | PRMT9, DHRS9, MRPL9 | AOC3 1525/4885SIGMAR1 2237/4885CHRM2 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.